OncoSec Medical Incorporated ONCS
Set alert
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 1.65M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -0.57
- Beta
- 2.00
- Short ratio
- 0.34
- Inst. own
- 5.83%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jun 27, 2023
- 50-d avg
- 0.419703
- 200-d avg
- 2.64
- 1y target
- 110.00
Key statistics
- Market cap
- 1.65M
- Enterprise value
- 5.60M
- Trailing P/E
- 0.00
- Forward P/E
- -0.57
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -20.31
- Beta
- 2.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -16.43M
- Total cash
- 3.68M
- Total debt
- 8.46M
- Return on equity
- -410.17%
- Shares outstanding
- 5.96M
- Short % of float
- 3.70%
- 50-day average
- 0.419703
- 200-day average
- 2.64
Analyst view
Consensus: hold
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Jun 27, 2023
Expected Jun 27, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jun 27, 2023 | Apr 1, 2023 | 0.00 | — | — | — |
| Mar 13, 2023 | Jan 1, 2023 | 0.00 | — | — | — |
| Dec 15, 2022 | Oct 1, 2022 | 0.00 | — | — | — |
| Oct 31, 2022 | Jul 1, 2022 | 0.00 | — | — | — |
| Jun 14, 2022 | Apr 1, 2022 | 0.00 | — | — | — |
| Mar 15, 2022 | Jan 1, 2022 | -2.42 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2022 | BTIG | down | Buy | Neutral |
| Mar 16, 2022 | BTIG | main | — | Buy |
| Mar 8, 2021 | BTIG | init | — | Buy |
| Nov 25, 2020 | Dawson James | init | — | Buy |
| Nov 25, 2020 | H.C. Wainwright | down | Buy | Neutral |
| Nov 25, 2020 | H.C. Wainwright | main | Buy | Buy |
About OncoSec Medical Incorporated
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- oncosec.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on ONCS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALPHA HOLDINGS, INC. | Unknown | Conversion of Exercise of derivative security | Feb 17, 2021 | 1,718,250 |
| BONSTEIN SARA M | Chief Operating Officer | Sale | Jan 15, 2020 | 41,389 |
| CHINA GRAND PHARMACEUTICAL & HEALTHCARE HOLDINGS LTD | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 15, 2021 | 0 |
| DALESANDRO MARGARET PH.D | Director | Purchase | Aug 22, 2021 | 20,000 |
| DELAVERSANO ROBERT J | Officer | Sale | Feb 8, 2023 | 1,008 |
| DEMESA JAMES M | Director | Stock Award(Grant) | Dec 16, 2018 | 22,501 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FNY Investment Advisers, LLC | 2.32% | 105,690 | 29.30K | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 1.26% | 57,488 | 15.94K | Mar 30, 2023 |
| State Street Corporation | 0.55% | 25,187 | 6.98K | Mar 30, 2023 |
| Salzhauer, Michael | 0.46% | 20,799 | 5.76K | Mar 30, 2023 |
| Bank Of New York Mellon Corporation | 0.38% | 17,434 | 4.83K | Mar 30, 2023 |
| LPL Financial LLC | 0.38% | 17,404 | 4.82K | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.25% | 7,517 | 2.08K | Feb 27, 2023 |
| Fidelity Series Total Market Index Fund | 0.03% | 1,003 | 278 | Feb 27, 2023 |
| Fidelity Total Market Index Fund | 0.03% | 895 | 248 | Feb 27, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 706 | 195 | Feb 27, 2023 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.00% | 56 | 15 | Feb 27, 2023 |